share_log

Oppenheimer Maintains Outperform on Corvus Pharma, Raises Price Target to $8

Benzinga ·  May 7 08:06

Oppenheimer analyst Jeff Jones maintains Corvus Pharma (NASDAQ:CRVS) with a Outperform and raises the price target from $7 to $8.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment